97.71

1.03% -1.02

After Hours: 97.71

Ani Pharmaceuticals Inc (ANIP)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Ani Pharmaceuticals Inc stock is traded at $97.71, with a volume of 210.86K. It is down -1.03% in the last 24 hours and up +10.61% over the past month. ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Previous Close:

$98.73

Open:

$98.42

24h Volume:

210.86K

Relative Volume:

0.47

Market Cap:

$2.12B

Revenue:

$486.82M

Net Income/Loss:

$18.78M

P/E Ratio:

119.16

EPS:

0.82

Net Cash Flow:

$100.45M

1W Performance:

+2.48%

1M Performance:

+10.61%

6M Performance:

+54.46%

1Y Performance:

+74.02%

1-Day Range:

$97.18

$99.10

1-Week Range:

$94.31

$99.50

52-Week Range:

$52.50

$99.50

Ani Pharmaceuticals Inc Stock (ANIP) Company Profile

Name

Ani Pharmaceuticals Inc

Sector

Healthcare (1152)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

(218) 634-3500

Address

210 MAIN STREET WEST, BAUDETTE, MN

Employee

897

Twitter

Next Earnings Date

2025-08-08

Latest SEC Filings

ANIP's Discussions on Twitter

Compare ANIP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANIP Ani Pharmaceuticals Inc	97.71	2.11B	486.82M	18.78M	100.45M	0.82
ZTS Zoetis Inc	148.20	66.22B	9.39B	2.62B	2.22B	5.81
TAK Takeda Pharmaceutical Co Adr	15.10	48.29B	29.96B	957.25M	4.77B	0.304
HLN Haleon Plc Adr	9.81	43.99B	14.26B	1.98B	2.47B	0.4347
TEVA Teva Pharmaceutical Industries Ltd Adr	19.93	22.45B	16.70B	-157.13M	1.19B	-0.155
UTHR United Therapeutics Corp	405.02	17.93B	2.99B	1.21B	1.13B	25.06

Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-10-25	Initiated	H.C. Wainwright	Buy
Mar-14-25	Initiated	Jefferies	Buy
Mar-12-25	Initiated	JP Morgan	Overweight
Dec-11-24	Initiated	Leerink Partners	Outperform
Oct-11-24	Initiated	Piper Sandler	Overweight
Mar-15-24	Initiated	CapitalOne	Overweight
Aug-22-23	Reiterated	H.C. Wainwright	Buy
Mar-01-23	Initiated	Guggenheim	Buy
Sep-07-22	Initiated	H.C. Wainwright	Buy
Nov-02-21	Initiated	Truist	Buy
May-07-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-19	Initiated	Guggenheim	Buy
May-10-19	Downgrade	Raymond James	Strong Buy → Outperform
Oct-16-17	Reiterated	Canaccord Genuity	Buy
Jul-31-17	Initiated	Canaccord Genuity	Buy
Feb-22-17	Downgrade	ROTH Capital	Buy → Neutral
Jun-23-16	Initiated	Raymond James	Strong Buy
May-24-16	Downgrade	Standpoint Research	Buy → Hold
Nov-13-15	Initiated	Standpoint Research	Buy
Sep-28-15	Upgrade	ROTH Capital	Neutral → Buy
Aug-05-15	Reiterated	Oppenheimer	Outperform
Aug-04-15	Reiterated	ROTH Capital	Neutral
Jul-31-15	Reiterated	Oppenheimer	Outperform
Jul-15-15	Reiterated	ROTH Capital	Neutral
Jun-23-15	Reiterated	Oppenheimer	Outperform
May-18-15	Reiterated	ROTH Capital	Neutral
May-06-15	Reiterated	Oppenheimer	Outperform
Apr-10-15	Downgrade	ROTH Capital	Buy → Neutral
Feb-26-15	Reiterated	ROTH Capital	Buy
Feb-18-15	Reiterated	Oppenheimer	Outperform

View All

Ani Pharmaceuticals Inc Stock (ANIP) Latest News

Sep 12, 2025